Document Detail


Selective and sustained delivery of basic fibroblast growth factor (bFGF) for treatment of peripheral arterial disease: results of a phase I trial.
MedLine Citation:
PMID:  19328029     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The aim of this study was to evaluate the safety of selective and sustained delivery of basic fibroblast growth factor (bFGF) using acidic gelatine hydrogel microspheres (AGHMs) for the treatment of peripheral arterial disease (PAD). MATERIALS AND METHODS: We conducted a non-randomised and uncontrolled trial involving prospective observation of eight patients (eight limbs) with PAD - five limbs with arteriosclerosis obliterans and three limbs with thromboangiitis obliterans, five limbs (three arms and two legs) with critical limb ischaemia (CLI) and three limbs with intermittent claudication (IC) - who were followed up for 6 months or more. AGHM suspension containing 100 microg bFGF was infused into the artery of the affected limb. Besides evaluation of safety and changes in symptoms, resting ankle-brachial pressure index measurement and transcutaneous PO(2) (tcPO(2)), angiography were conducted at baseline and then at various time points. Skin perfusion pressure as an index of CLI and claudication distance as an index of IC were also used to assess clinical improvement and limb perfusion. RESULTS: No serious adverse events were observed. All cases showed improvement in symptoms, although this was temporary in some patients. CONCLUSION: Selective delivery of bFGF using AGHMs was suggested to be safe and well-tolerated in patients with PAD.
Authors:
T Hashimoto; H Koyama; T Miyata; A Hosaka; Y Tabata; T Takato; H Nagawa
Related Documents :
19640919 - Is atherectomy the best first-line therapy for limb salvage in patients with critical l...
20354489 - The use of the cryoplasty technique in the treatment of infrapopliteal lesions for crit...
11193719 - Lower limb revascularization and free flap transfer for major ischemic tissue loss.
12799759 - Risk of amputation following limb salvage surgery with endoprosthetic replacement, in a...
7788599 - The traumatized ischemic lower limb: a search for the optimal treatment.
20299119 - Comparison of post amputation outcome in patients with type 2 diabetes from specialized...
12968119 - The experience of manual lymph drainage as an aspect of treatment for lymphoedema.
12436119 - Impact of early surgical correction of curves in paralytic scoliosis.
18675689 - Effect of eradication of helicobacter pylori on incidence of metachronous gastric carci...
Publication Detail:
Type:  Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-03-26
Journal Detail:
Title:  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery     Volume:  38     ISSN:  1532-2165     ISO Abbreviation:  Eur J Vasc Endovasc Surg     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-15     Completed Date:  2009-06-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9512728     Medline TA:  Eur J Vasc Endovasc Surg     Country:  England    
Other Details:
Languages:  eng     Pagination:  71-5     Citation Subset:  IM    
Affiliation:
Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Angiography
Arteriosclerosis Obliterans / drug therapy,  physiopathology,  radiography
Blood Pressure / drug effects,  physiology
Delayed-Action Preparations
Female
Fibroblast Growth Factor 2 / administration & dosage*
Follow-Up Studies
Humans
Injections, Intra-Arterial
Intermittent Claudication / drug therapy,  physiopathology,  radiography
Male
Microspheres
Middle Aged
Peripheral Vascular Diseases / drug therapy*,  physiopathology,  radiography
Prospective Studies
Thromboangiitis Obliterans / drug therapy,  physiopathology,  radiography
Treatment Outcome
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 103107-01-3/Fibroblast Growth Factor 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antibiotic prophylaxis for the prevention of infection after major limb amputation.
Next Document:  WITHDRAWN: Transplant.